Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Um estudo de JNJ-89402638 para câncer colorretal metastático

2 de novembro de 2026 atualizado por: Janssen Research & Development, LLC

Um estudo de fase I de JNJ-89402638 para câncer colorretal metastático irressecável

The purpose of this study is to determine the putative recommended phase 2 dose(s) (RP2Ds) and best way to take (optimal route of administration) JNJ-89402638 and to determine the safety of JNJ-89402638 at the RP2D(s) in participants with metastatic colorectal cancer (mCRC) and metastatic gastric cancer (mGAC) and to determine the safety and tolerability of JNJ-89402638 in combination with bevacizumab or biosimilar with or without chemotherapy in participants with mCRC.

Visão geral do estudo

Tipo de estudo

Intervencional

Inscrição (Estimado)

260

Estágio

  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

      • Seoul, Coréia do Sul, 05505
        • Recrutamento
        • Asan Medical Center
      • Seoul, Coréia do Sul, 03722
        • Recrutamento
        • Severance Hospital Yonsei University Health System
      • Barcelona, Espanha, 08035
        • Recrutamento
        • Hosp Univ Vall D Hebron
      • Madrid, Espanha, 28041
        • Recrutamento
        • Hosp. Univ. 12 de Octubre
      • Madrid, Espanha, 28040
        • Recrutamento
        • Hosp Univ Fund Jimenez Diaz
      • Madrid, Espanha, 28050
        • Recrutamento
        • Hosp Univ Hm Sanchinarro
    • Arizona
      • Tucson, Arizona, Estados Unidos, 85719
        • Recrutamento
        • University of Arizona Cancer Center
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Recrutamento
        • University of Colorado Denver Anschultz Medical Campus
    • Florida
      • Sarasota, Florida, Estados Unidos, 34232
        • Recrutamento
        • Florida Cancer Specialists
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46256
        • Recrutamento
        • Community Health Network
    • Michigan
      • Grand Rapids, Michigan, Estados Unidos, 49546
        • Recrutamento
        • Start Midwest
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • Recrutamento
        • Swedish Cancer Institute

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • For Part 1 (dose escalation), Part 2 (Arm A [JNJ-89402638 monotherapy]): Have histologically or cytologically confirmed diagnosis of colorectal adenocarcinoma (CRC) progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting; For Part 2 Arm B (JNJ-89402638 + bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of CRC progressing after 2 or more prior lines of standard therapy in the metastatic/unresectable setting; For Part 2 Arm C (JNJ-89402638 + FOLFOX/bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of microsatellite stable (MSS) or proficient mismatch repair (pMMR) CRC progressing after 1 or more prior lines of standard therapy in the metastatic/unresectable setting. Participants must have previously received a fluoropyrimidine and irinotecan doublet (such as FOLFIRI); For Part 2 Arm D (JNJ-89402638 + FOLFIRI/bevacizumab or biosimilar): Have histologically or cytologically confirmed diagnosis of MSS or pMMR CRC progressing after 1 prior line of standard therapy in the metastatic/unresectable setting. Must not have received irinotecan previously for metastatic disease; For Part 2 Arm E (JNJ-89402638 monotherapy in mGAC): Have histologically or cytologically confirmed diagnosis of gastric adenocarcinoma or gastroesophageal junction adenocarcinoma progressing after 1 or more prior lines of standard therapy in the metastatic/unresectable setting

  • Have evaluable or measurable disease per response evaluation criteria in solid tumors (RECIST) version 1.1

    1. Part 1: Must have either measurable or evaluable disease
    2. Part 2: Must have at least 1 measurable lesion
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

  • Have an estimated or measured glomerular filtration rate (GFR) greater than or equal to (>=) 30 milliliter per minute (mL/min) based on modification of diet in renal disease (MDRD) 4-variable formula

Exclusion Criteria:

  • Active (new or progressive) brain metastases, leptomeningeal disease, or untreated spinal cord compression
  • Toxicity from prior anticancer therapy that has not resolved to Grade less than or equal to (<=)1 (except alopecia, vitiligo, Grade <= 2 peripheral neuropathy, or endocrinopathies that are stable on hormone replacement). For Part 2 Arm C: Grade 2 or higher peripheral neuropathy is considered exclusionary
  • Has a prior or concurrent second malignancy (other than the disease under study) unless natural history or treatment is unlikely to interfere with any study endpoints of safety or the efficacy of the study treatment
  • Received glucocorticoids (doses >10 mg/day prednisone or equivalent) within 7 days prior to the first dose of study drug
  • Received or plans to receive any live, attenuated vaccine within 4 weeks before the first dose of study treatment or within 4 weeks after the last dose of study treatment

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Não randomizado
  • Modelo Intervencional: Atribuição sequencial
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Part 1 (Dose Expansion)

Participants with unresectable metastatic colorectal adenocarcinoma (mCRC) will receive JNJ-89402638 in Part 1 (Dose escalation) of the study and the dose levels will be escalated sequentially until the recommended Phase 2 Dose(s) (RP2D) and optimal route(s) of administration for JNJ-89402638 monotherapy have been identified.

JNJ-89402638 will be administered.

Experimental: Part 2 (Dose Expansion): Arm A

Participants with mCRC will receive JNJ-89402638 at the RP2D(s) and route as determined in Part 1 as a monotherapy.

JNJ-89402638 will be administered.

Experimental: Part 2 (Dose Expansion): Arm B

Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 along with bevacizumab or biosimilar.

JNJ-89402638 will be administered.

Bevacizumab or biosimilar will be administered.

Experimental: Part 2 (Dose Expansion): Arm C

Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 along with bevacizumab or biosimilar and FOLFOX.

JNJ-89402638 will be administered.

Bevacizumab or biosimilar will be administered.

Chemotherapy agent FOLFOX will be administered.

Experimental: Part 2 (Dose Expansion): Arm D

Participants with mCRC will receive JNJ-89402638 at the RP2D(s) determined in Part 1 in combination with bevacizumab or biosimilar and FOLFIRI.

JNJ-89402638 will be administered.

Bevacizumab or biosimilar will be administered.

Chemotherapy agent FOLFIRI will be administered.

Experimental: Part 2 (Dose Expansion): Arm E

Participants with metastatic gastric adenocarcinoma (mGAC) will receive JNJ-89402638 at the RP2D(s) and route as determined in Part 1.

JNJ-89402638 will be administered.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Part 1 and Part 2: Number of Participants with Adverse Events (AEs) by Severity
Prazo: From Baseline up to approximately 24 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded per American Society for Transplantation and Cellular Therapy (ASTCT) consensus.

From Baseline up to approximately 24 months
Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)
Prazo: From Baseline up to 28 days

The DLTs are specific adverse events including high grade hematologic or non-hematologic toxicities.

From Baseline up to 28 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Part 1 and Part 2: Serum Concentration for JNJ-89402638
Prazo: Up to approximately 24 months

Serum Concentration for JNJ-89402638 will be reported.

Up to approximately 24 months
Part 1 and Part 2: Maximum Serum Concentration (Cmax) of JNJ-89402638
Prazo: Up to approximately 24 months

Cmax of JNJ-89402638 will be reported.

Up to approximately 24 months
Part 1 and Part 2: Minimum Serum Concentration (Cmin) of JNJ-89402638
Prazo: Up to approximately 24 months

Cmin of JNJ-89402638 will be reported.

Up to approximately 24 months
Part 1 and Part 2: Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-89402638
Prazo: Up to approximately 24 months

Tmax of JNJ-89402638 will be reported.

Up to approximately 24 months
Part 1 and Part 2: Area Under the Serum Concentration-time Curve (AUC) of JNJ-89402638
Prazo: Up to approximately 24 months

AUC of JNJ-89402638 will be reported.

Up to approximately 24 months
Part 1 and Part 2: Number of Participants with Presence of Anti-JNJ-89402638 Antibodies
Prazo: Up to approximately 24 months

Participants with anti-JNJ-89402638 antibodies will be reported.

Up to approximately 24 months
Part 1 and Part 2: Overall Response (OR)
Prazo: Up to approximately 24 months

Overall response is best response of complete response (CR) or partial response (PR), assessed according to response evaluation criteria in solid tumors (RECIST) version 1.1.

Up to approximately 24 months
Part 1 and Part 2: Complete Response (CR)
Prazo: Up to approximately 24 months

Complete response is defined as a best response of CR assessed according to RECIST version 1.1.

Up to approximately 24 months
Part 1 and Part 2: Time to Response (TTR)
Prazo: Up to approximately 24 months

TTR is defined for participants who achieved an OR from the time of the first dose of study treatment to the first response of PR or better as assessed according to RECIST version 1.1.

Up to approximately 24 months
Part 1 and Part 2: Duration of Response (DOR)
Prazo: Up to approximately 24 months

DOR is defined for participants who achieved an OR in the time between the date of initial documentation of first response of PR or better to the date of first documented evidence of progressive disease or death due to any cause, whichever occurs first, as assessed according to RECIST version 1.1

Up to approximately 24 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Diretor de estudo: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

15 de outubro de 2024

Conclusão Primária (Estimado)

25 de fevereiro de 2028

Conclusão do estudo (Estimado)

19 de julho de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

28 de outubro de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

28 de outubro de 2024

Primeira postagem (Real)

29 de outubro de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

3 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

2 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever